Reviews Estradiol, Norethindrone Acetate


No reviews yet.

Activella Drug Description
Activella®
(estradiol/norethindrone acetate) 1.0 mg/0.5 mg 0.5 mg/0.1 mg Tablets


CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen plus progestin substudy of the Women's Health Initiative (WHI)
reported increased risks of myocardial infarction, stroke, invasive breast
cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with oral conjugated
estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5
mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The estrogen-alone substudy of the WHI reported increased risks of stroke
and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of
age) during 6.8 years and 7.1 years, respectively, of treatment with oral
conjugated estrogens (CE 0.625 mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI
study, reported increased risk of developing probable dementia in postmenopausal
women 65 years of age or older during 4 years of treatment with CE 0.625 mg
combined with MPA 2.5 mg and during 5.2 years of treatment with CE 0.625 mg
alone, relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women. (See Clinical Studies,
WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these trials, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and norethindrone (Activella)?

If you experience any of the following serious side effects, stop taking estradiol and norethindrone and seek emergency medical attention or notify your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
shortness of breath or pain in the chest;
a painful, red, swollen leg;
abnormal vaginal bleeding;
pain, swelling, or tenderness in the...
Read All Potential Side Effects for Activella »




Activella 1.0 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin.
Activella 0.5 mg/0.1 mg is a single tablet for oral administration containing 0.5 mg of estradiol and 0.1 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), hydroxypropylcellulose, talc, magnesium stearate, hypromellose and triacetin.
Estradiol (E2) is a white or almost white crystalline powder. Its
chemical name is estra-1, 3, 5 (10)-triene-3, 17β-diol hemihydrate with
the empirical formula of C18H24O2, ½ H2O
and a molecular weight of 281.4. The structural formula of E2 is
as follows:








Norethindrone acetate (NETA) is a white or yellowish-white crystalline powder.
Its chemical name is 17β-acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one
with the empirical formula of C22H28O3 and
molecular weight of 340.5. The structural formula of NETA is as follows:







Last reviewed on RxList: 9/29/2008




Activella Drug Description
Activella®
(estradiol/norethindrone acetate) 1.0 mg/0.5 mg 0.5 mg/0.1 mg Tablets


CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen plus progestin substudy of the Women's Health Initiative (WHI)
reported increased risks of myocardial infarction, stroke, invasive breast
cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with oral conjugated
estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5
mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The estrogen-alone substudy of the WHI reported increased risks of stroke
and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of
age) during 6.8 years and 7.1 years, respectively, of treatment with oral
conjugated estrogens (CE 0.625 mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI
study, reported increased risk of developing probable dementia in postmenopausal
women 65 years of age or older during 4 years of treatment with CE 0.625 mg
combined with MPA 2.5 mg and during 5.2 years of treatment with CE 0.625 mg
alone, relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women. (See Clinical Studies,
WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these trials, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and norethindrone (Activella)?

If you experience any of the following serious side effects, stop taking estradiol and norethindrone and seek emergency medical attention or notify your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
shortness of breath or pain in the chest;
a painful, red, swollen leg;
abnormal vaginal bleeding;
pain, swelling, or tenderness in the...
Read All Potential Side Effects for Activella »




Activella 1.0 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin.
Activella 0.5 mg/0.1 mg is a single tablet for oral administration containing 0.5 mg of estradiol and 0.1 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), hydroxypropylcellulose, talc, magnesium stearate, hypromellose and triacetin.
Estradiol (E2) is a white or almost white crystalline powder. Its
chemical name is estra-1, 3, 5 (10)-triene-3, 17β-diol hemihydrate with
the empirical formula of C18H24O2, ½ H2O
and a molecular weight of 281.4. The structural formula of E2 is
as follows:








Norethindrone acetate (NETA) is a white or yellowish-white crystalline powder.
Its chemical name is 17β-acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one
with the empirical formula of C22H28O3 and
molecular weight of 340.5. The structural formula of NETA is as follows:







Last reviewed on RxList: 9/29/2008




Activella Drug Description
Activella®
(estradiol/norethindrone acetate) 1.0 mg/0.5 mg 0.5 mg/0.1 mg Tablets


CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen plus progestin substudy of the Women's Health Initiative (WHI)
reported increased risks of myocardial infarction, stroke, invasive breast
cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with oral conjugated
estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5
mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The estrogen-alone substudy of the WHI reported increased risks of stroke
and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of
age) during 6.8 years and 7.1 years, respectively, of treatment with oral
conjugated estrogens (CE 0.625 mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI
study, reported increased risk of developing probable dementia in postmenopausal
women 65 years of age or older during 4 years of treatment with CE 0.625 mg
combined with MPA 2.5 mg and during 5.2 years of treatment with CE 0.625 mg
alone, relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women. (See Clinical Studies,
WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these trials, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and norethindrone (Activella)?

If you experience any of the following serious side effects, stop taking estradiol and norethindrone and seek emergency medical attention or notify your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
shortness of breath or pain in the chest;
a painful, red, swollen leg;
abnormal vaginal bleeding;
pain, swelling, or tenderness in the...
Read All Potential Side Effects for Activella »




Activella 1.0 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin.
Activella 0.5 mg/0.1 mg is a single tablet for oral administration containing 0.5 mg of estradiol and 0.1 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), hydroxypropylcellulose, talc, magnesium stearate, hypromellose and triacetin.
Estradiol (E2) is a white or almost white crystalline powder. Its
chemical name is estra-1, 3, 5 (10)-triene-3, 17β-diol hemihydrate with
the empirical formula of C18H24O2, ½ H2O
and a molecular weight of 281.4. The structural formula of E2 is
as follows:








Norethindrone acetate (NETA) is a white or yellowish-white crystalline powder.
Its chemical name is 17β-acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one
with the empirical formula of C22H28O3 and
molecular weight of 340.5. The structural formula of NETA is as follows:







Last reviewed on RxList: 9/29/2008




Activella Drug Description
Activella®
(estradiol/norethindrone acetate) 1.0 mg/0.5 mg 0.5 mg/0.1 mg Tablets


CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen plus progestin substudy of the Women's Health Initiative (WHI)
reported increased risks of myocardial infarction, stroke, invasive breast
cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with oral conjugated
estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5
mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The estrogen-alone substudy of the WHI reported increased risks of stroke
and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of
age) during 6.8 years and 7.1 years, respectively, of treatment with oral
conjugated estrogens (CE 0.625 mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI
study, reported increased risk of developing probable dementia in postmenopausal
women 65 years of age or older during 4 years of treatment with CE 0.625 mg
combined with MPA 2.5 mg and during 5.2 years of treatment with CE 0.625 mg
alone, relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women. (See Clinical Studies,
WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these trials, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and norethindrone (Activella)?

If you experience any of the following serious side effects, stop taking estradiol and norethindrone and seek emergency medical attention or notify your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
shortness of breath or pain in the chest;
a painful, red, swollen leg;
abnormal vaginal bleeding;
pain, swelling, or tenderness in the...
Read All Potential Side Effects for Activella »




Activella 1.0 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin.
Activella 0.5 mg/0.1 mg is a single tablet for oral administration containing 0.5 mg of estradiol and 0.1 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), hydroxypropylcellulose, talc, magnesium stearate, hypromellose and triacetin.
Estradiol (E2) is a white or almost white crystalline powder. Its
chemical name is estra-1, 3, 5 (10)-triene-3, 17β-diol hemihydrate with
the empirical formula of C18H24O2, ½ H2O
and a molecular weight of 281.4. The structural formula of E2 is
as follows:








Norethindrone acetate (NETA) is a white or yellowish-white crystalline powder.
Its chemical name is 17β-acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one
with the empirical formula of C22H28O3 and
molecular weight of 340.5. The structural formula of NETA is as follows:







Last reviewed on RxList: 9/29/2008




Activella Drug Description
Activella®
(estradiol/norethindrone acetate) 1.0 mg/0.5 mg 0.5 mg/0.1 mg Tablets


CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Dementia.)
The estrogen plus progestin substudy of the Women's Health Initiative (WHI)
reported increased risks of myocardial infarction, stroke, invasive breast
cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women
(50 to 79 years of age) during 5.6 years of treatment with oral conjugated
estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5
mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The estrogen-alone substudy of the WHI reported increased risks of stroke
and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of
age) during 6.8 years and 7.1 years, respectively, of treatment with oral
conjugated estrogens (CE 0.625 mg) per day, relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI
study, reported increased risk of developing probable dementia in postmenopausal
women 65 years of age or older during 4 years of treatment with CE 0.625 mg
combined with MPA 2.5 mg and during 5.2 years of treatment with CE 0.625 mg
alone, relative to placebo. It is unknown whether this finding applies to
younger postmenopausal women. (See Clinical Studies,
WARNINGS, Dementia and PRECAUTIONS,
Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these trials, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and norethindrone (Activella)?

If you experience any of the following serious side effects, stop taking estradiol and norethindrone and seek emergency medical attention or notify your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
shortness of breath or pain in the chest;
a painful, red, swollen leg;
abnormal vaginal bleeding;
pain, swelling, or tenderness in the...
Read All Potential Side Effects for Activella »




Activella 1.0 mg/0.5 mg is a single tablet for oral administration containing 1 mg of estradiol and 0.5 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), copovidone, talc, magnesium stearate, hypromellose and triacetin.
Activella 0.5 mg/0.1 mg is a single tablet for oral administration containing 0.5 mg of estradiol and 0.1 mg of norethindrone acetate and the following excipients: lactose monohydrate, starch (corn), hydroxypropylcellulose, talc, magnesium stearate, hypromellose and triacetin.
Estradiol (E2) is a white or almost white crystalline powder. Its
chemical name is estra-1, 3, 5 (10)-triene-3, 17β-diol hemihydrate with
the empirical formula of C18H24O2, ½ H2O
and a molecular weight of 281.4. The structural formula of E2 is
as follows:








Norethindrone acetate (NETA) is a white or yellowish-white crystalline powder.
Its chemical name is 17β-acetoxy-19-nor-17α-pregn-4-en-20-yn-3-one
with the empirical formula of C22H28O3 and
molecular weight of 340.5. The structural formula of NETA is as follows:







Last reviewed on RxList: 9/29/2008





Other reviews about Estradiol, Norethindrone Acetate on wordpress

но мать ебется с сыном
  by admin
A good diet to stabilize hyperglycemia Tagamet and zantac interaction Diet food delivered long grove illinois Glucosamine sulfate and bright yellow urine Talking insulin pump Sildenafil increaser Uses of zinc carbonate Acute exposure to potassium […]


Doctor, will estrogen therapy cause me to have a stroke?
  by drbloem
After having been referred to me by a colleague, a woman who was interested in bioidentical hormone therapy contacted me. She told me that she had suffered a […]


FDA Approved Bioidentical Hormones
  by bodylogicmd
We've mentioned that the FDA has approved over 20 bioidentical hormones and now want to share some of the hormones on that list, specifically those meant to treat […]


Online Pharmacy Walgreenss online pharmacy
  by gavincmasonu
Ampicillin, amoxycillin, antibiotics cefaclor, tetracycline, chloramphenicol, trimethoprim/sulphamethoxazole. The intraocular inflammation disappeared within 4 weeks in seven patients, including two cases with progressive retinitis despite previous treatment with pyrimethamine, […]


Contraceptive hormone linked to breast cancer, teens at risk
  by drbloem
For those familiar with the Women's Health Initiative (WHI) that was sponsored by the National Institutes of Health the link between oral contraceptives and breast cancer is no […]


Herbs Clearwater florida herbs
  by terryndennisy
Pylori, combined with a proton-pump inhibitor and two antibiotics (clarithromycin and amoxicillin) is restrictedly approved in the patients with gastric or duodenal ulcer by Japanese health care system.. […]


IVF: Part Two
  by babybaker
PART TWO: Continue Norethindrone twice daily through Friday, 1/1. Begin 20 units of Lupron, which I did last night at 11pm. OMG, it's finally here! I actually injected myself […]


Ovarian steroid hormones differentially regulate thrombospondin-1 expression
  by fertstert
To the Editor: We read with great interest the article of Tan et al. (1) which reported that thrombospodin-1 (TSP-1), a multifunctional extracellular naturally occurring angiostatic protein is […]


Hormonal Contraceptives and Acne
  by thescienceofacne
Many women report significant changes in the frequency and severity of their acne outbreaks after beginning a program of hormonal contraceptives.  For many women the use hormonal birth […]



Other reviews about Estradiol, Norethindrone Acetate on web:

Estradiol/Norethindrone Acetate professional patient advice. Specific and up to date information about Estradiol/Norethindrone Acetate. Complete Estradiol/Norethindrone Acetate information from Drugs.com


norethindrone acetate n trade names: Aygestin, Micronor, Norlutate, Norlutin, Nor-QD; drug class: progesterone derivative; action: inhibits secretion norethindrone acetate: Definition from Answers.com


Learn about the prescription medication Activella (Estradiol, Norethindrone Acetate), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Activella (Estradiol, Norethindrone Acetate) Drug Information ...


Ethinyl Estradiol; Norethindrone Acetate tablets To return to the main entry click here . What are ethinyl estradiol; norethindrone acetate tablets? Ethinyl Estradiol; Norethindrone Acetate tablets: Information from ...


Comprehensive and trusted information about Estradiol/norethindrone acetate - plus advice on 24,000 other FDA approved drugs and medications from Drugs.com. Estradiol/norethindrone acetate patient advice including side effects


Activella estradiol/norethindrone acetate tablets + About menopause. Overview; Stages; Symptoms; Postmenopausal health; Menopause FAQs + About hot flashes Plant-derived Hormone Therapy (HT) for Menopausal Symptoms ...


Consumer information about the medication NORETHINDRONE ACETATE/ETHINYL ESTRADIOL W/ FERROUS FUMARATE ORAL (Estrostep Fe, Loestrin Fe), includes side effects, drug interactions ... NORETHINDRONE ACETATE/ETHINYL ESTRADIOL W/ FERROUS FUMARATE ORAL ...


femhrt ® (norethindrone acetate/ethinyl estradiol tablets ) WARNING Estrogens and progestins should not be used for the prevention of cardiovascular disease or dementia. norethindrone acetate/ethinyl estradiol tablets )


Learn about the prescription medication CombiPatch (Estradiol, Norethindrone Acetate Transdermal System), drug uses, dosage, side effects, drug interactions, warnings, reviews ... CombiPatch (Estradiol, Norethindrone Acetate Transdermal System ...


Drug information and side-effects for Activella (Estradiol/Norethindrone Acetate) Tablets Activella (Estradiol/Norethindrone Acetate) Tablets - Drug ...





Featured Reviews

Reviews Rabeprazole Sodium

Aciphex Drug Description ACIPHEX (rabeprazole sodium) Delayed Release Tablets DRUG DESCRIPTION What are the possible side effects of rabeprazole (Aciphex)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Capsaicin 8% Patch

Qutenza Drug Description QUTENZA™ (capsaicin) 8% Patch DRUG DESCRIPTION Qutenza (capsaicin) 8% patch contains capsaicin in a localized dermal delivery system. The capsaicin in Qutenza is a synthetic equivalent of the naturally occurring...
Read More  |  Review This
Reviews Trimethoprim

Trimethoprim Drug Description TRIMETHOPRIM (trimethoprim) Tablet DRUG DESCRIPTION Trimethoprim is a synthetic antibacterial available as 100 mg tablets for oral administration. Trimethoprim is 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)...
Read More  |  Review This
Reviews Morphine Sulfate XR Liposome Injection

DepoDur Drug Description DepoDur® (morphine sulfate) Extended-Release Liposome Injection DRUG DESCRIPTION DepoDur (morphine sulfate) extended-release liposome injection is a sterile suspension of multivesicular liposomes using proprietary...
Read More  |  Review This
Reviews Methamphetamine Hydrochloride

Desoxyn Drug Description DESOXYN® (methamphetamine hydrochloride) Tablets, USP METHAMPHETAMINE HAS A HIGH POTENTIAL FOR ABUSE. IT SHOULD THUS BE TRIED ONLY IN WEIGHT REDUCTION PROGRAMS FOR PATIENTS IN WHOM ALTERNATIVE THERAPY...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....